Riyadh, November 11, 2024 – King Faisal Specialist Hospital & Research Centre (KFSHRC) has announced a groundbreaking advancement in stem cell science, securing a United States patent for a pioneering technique that holds transformative potential for breast cancer treatment and regenerative medicine. In a statement released by KFSHRC, the institution highlighted the work of researchers Abdelilah Aboussekhra, Huda H. Al-Khalaf, and Hazem Ghebeh, whose innovative approach centers on reprogramming normal breast cells into multipotent stem cells using specialized culture methods. This development offers promising new possibilities in breast tissue reconstruction and targeted cancer therapies.
The newly patented technique has shown remarkable results in preclinical trials, with the reprogrammed stem cells demonstrating the capacity to regenerate mammary tissue in animal models. This breakthrough provides an important foundation for the future of personalized breast cancer treatments, potentially offering patients enhanced options for tissue reconstruction and improved recovery outcomes post-surgery. The scientific basis for this work was published in the journal Molecular and Cellular Biology, which underscored the innovation’s potential impact on both regenerative medicine and oncology.
This achievement also highlights KFSHRC’s broader mission to address critical needs in cancer treatment. The research center has consistently pushed the boundaries of personalized cancer therapies, including localized CAR T-cell treatments that represent a highly targeted approach to combating specific types of cancer. Through its commitment to pioneering treatments, KFSHRC continues to set new standards in personalized and transformative medical care, working to enhance therapeutic outcomes for patients worldwide.
In recognition of its excellence and dedication to advanced medical research, KFSHRC has earned several prestigious accolades. The hospital has been ranked as the top academic medical center in the Middle East and Africa and placed 20th globally in the list of the world’s top 250 Academic Medical Centers for the second consecutive year. Additionally, Brand Finance recognized KFSHRC as the most valuable healthcare brand in both the Kingdom and the Middle East for 2024. Furthermore, KFSHRC has been included in the list of the World’s Best Smart Hospitals for 2025 by Newsweek magazine, a testament to its commitment to integrating innovative technologies in healthcare.
With this latest achievement in stem cell science, KFSHRC reaffirms its leadership in cutting-edge medical research, underscoring its role in shaping the future of personalized healthcare and advanced cancer treatments.
